Find a Physician | How to Contribute | About Us | Clinical Trials

Gradishar Named Interim Chief, Division of Hematology/Oncology

William Gradishar, MD

William Gradishar, MD, Deputy Director for the Lurie Cancer Center’s Clinical Network, has been appointed Interim Chief of the Division of Hematology/Oncology in the Department of Medicine, where he will foster the growth and success of the division’s clinical, research and academic pursuits. The Department of Medicine will conduct a national search for the next Division Chief.

Gradishar is the Betsy Bramsen Professor of Breast Oncology, and Professor of Medicine in the Division of Hematology / Oncology at Northwestern University Feinberg School of Medicine. He is also Director of the Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials of new therapeutic approaches for breast cancer. 

Dr. Gradishar has served as Chair of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium, a nationally recognized, four-day meeting for the practicing clinician, since its inception in 1998. His research focuses on the development of adjuvant therapies and novel therapeutics for the treatment of breast cancer. 

A Fellow of the American College of Physicians and a Fellow of the American Society of Clinical Oncology (ASCO), Dr. Gradishar is also a member of the American Association for Cancer Research, and the American Federation for Clinical Research. He has held numerous leadership positions in ASCO, been a member of numerous Study Sections for funding agencies including the Department of Defense, NIH, Komen Foundation, and American Cancer Society. He has served as a consultant to the FDA Oncology Drug Advisory Committee (ODAC).  He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group (ECOG). Gradishar is Chair of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guideline Panel and a member of the Breast Cancer Prevention Panel. He was recently appointed Chair of the Breast Cancer Working Group for the Moonshot 2020 Initiative which will spearhead the development of novel therapeutics for the treatment of breast cancer.

Dr. Gradishar is a member of the editorial boards of the Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Cancer, European Journal of Medical Oncology, Oncology and Editor-in-Chief of NEJM Journal Watch: Oncology and Hematology.

(Last updated on April 4, 2017 )